Magnetic resonance imaging (MRI)-guided radiotherapy allows for smaller treatment margins in patients with high-grade glioma, according to a phase II trial (UNITED) published in The Lancet Oncology. Researchers at the Sunnybrook Health Sciences Centre found this technique resulted in a 4% marginal failure rate, suggesting that precision-guided adaptation can safely reduce the volume of healthy brain tissue exposed to radiation.
How MRI-Guided Radiotherapy Changes Treatment Margins
Standard radiation therapy for high-grade glioma typically requires wide margins to account for potential tumor spread. The UNITED trial, led by Jay Detsky, MD, PhD, utilized 1.5 T MRI-guided linear accelerators (MR-Linac) to provide weekly gadolinium-enhanced online adaptive fractions. By using a 5-mm clinical target volume—with adjustments for T2-weighted fluid-attenuated inversion recovery hyperintense regions—clinicians could tailor the radiation field to the individual patient’s anatomy.
The UNITED trial included two distinct treatment schedules: a 6-week “long course” of 60 Gy in 30 fractions and a 3-week “short course” of 40 Gy in 15 fractions.
What Were the Clinical Outcomes?
Of the 98 patients enrolled between April 2021 and May 2023, the incidence of marginal failure was 4% after a median follow-up of 14.2 months. According to the study data, the 95% confidence interval for this failure rate was 0% to 8%, which met the investigators’ criteria for noninferiority compared to historical controls. Among the four patients who experienced marginal failure, three had undergone the long-course radiation protocol, while one had received the short-course treatment.
Managing Treatment Toxicity
Precision-guided radiotherapy aims to reduce adverse side effects by minimizing exposure to healthy brain tissue. The study reported that serious adverse events were rare, occurring in only 1% of the cohort (one patient with febrile neutropenia). The most frequent grade 3 or 4 adverse events were lymphopenia, affecting 11% of patients who did not have the condition at baseline, and thrombocytopenia, which occurred in 4% of the total study population. No treatment-related deaths were recorded during the study period.
Comparison of Radiation Protocols
| Protocol | Patient Count | Marginal Failures |
|---|---|---|
| Long-Course (60 Gy) | 59 | 3 |
| Short-Course (40 Gy) | 39 | 1 |
What Happens Next in Glioma Research?
The investigators concluded that while MRI-guided adaptation enables successful margin de-escalation, further validation is necessary. A randomized trial comparing this adaptive technique against standard large-margin radiotherapy is needed to determine if the approach leads to measurable improvements in patient quality of life and long-term toxicity profiles. Currently, there is no external funding for the study, according to the authors’ disclosures.
Frequently Asked Questions
What is the primary benefit of MRI-guided radiotherapy for glioma?
It allows for “margin de-escalation,” meaning doctors can treat smaller areas around the tumor, potentially sparing healthy brain tissue from radiation damage.
Was the treatment considered safe?
Yes, serious adverse events were limited to 1% of participants, and no treatment-related deaths occurred, according to the findings published in The Lancet Oncology.
How many patients were involved in the trial?
The trial, conducted at the Sunnybrook Health Sciences Centre in Toronto, monitored 98 patients over a two-year enrollment period.
Are you interested in the latest developments in neuro-oncology and radiation therapy? Subscribe to our newsletter for updates on clinical trial outcomes and emerging treatment protocols.
Worth a look